Affiliation:
1. Department of Nursing Practices, Poznan University of Medical Sciences, 61-701 Poznan, Poland
2. Wielkopolska Oncology Centre Poznan, 61-866 Poznan, Poland
3. Department of Medical Chemistry and Laboratory Medicine, Poznan University of Medical Sciences, 61-701 Poznan, Poland
4. Department of Stem Cells and Regenerative Medicine, Institute of Natural Fibres and Medicinal Plants-National Research, 62-064 Plewiska, Poland
Abstract
Ovarian cancer is the worst prognostic gynaecological cancer and represents a grave clinical and social problem. Therefore, the study aimed to assess female patients’ emotional, cognitive, physical, and social quality of life. The study included 100 patients diagnosed with ovarian cancer and treated with chemotherapy in a day hospital setting at the Department of Radiotherapy and Gynaecological Oncology at the Wielkopolska Oncology Centre in Poznań. The patients were given a standard treatment regimen: paclitaxel 175 mg/m2 in a 3 h infusion and carboplatin at an AUC of 6 (5–7) following Calvert as a 1 h infusion for six cycles administered every 21 days. In addition, standardised questionnaires of the Polish version of the EORTC QLQ-C30 and QLQOV28 were used. The analysis of the collected material shows that the patients reported the highest level of general health and quality of life at the study’s first stage, i.e., before chemotherapy (mean value of 59.67 points). In contrast, the patients’ lowest level of general health and quality of life was observed in the fourth stage of the study (mean value of 45.04 points). The problem of side effects, such as nausea and vomiting, affected the entire study group and was more troublesome in the final stage of treatment for all patients. In the study’s first stage, the mean score on the nausea and vomiting symptom scale was 16 points; in the fourth stage, the mean score was 40.07. Of the clinical factors, the symptom of fatigue was the most severe health problem for the subjects. The mean score of the fatigue scale in the study’s first stage was 37.11 points, while a score of 70.33 was obtained in the fourth stage of the research. The multivariate linear regression model showed that the lack of professional activity lowers quality of life, especially combined with other side effects of chemotherapy, including hair loss in Stage IV of the study. This study shows that women with ovarian cancer undergoing chemotherapy need exceptional support from psychologists, nurses, dieticians, and physiotherapists.
Subject
Health Information Management,Health Informatics,Health Policy,Leadership and Management
Reference39 articles.
1. Epidemiology of ovarian cancer;Chin. Clin. Oncol.,2020
2. Epidemiology of ovarian cancer: A review;Brett;Cancer Biol. Med.,2017
3. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018
4. Ocena jakości życia kobiet z chorobą nowotworową leczonych metodą chemioterapii;Pr. Nauk. Uniw. Ekon. We Wrocławiu,2017
5. Quality of life for women treated for ovarian cancer;Perkowska;Pieleg. Chir. Angiol/Surg. Vasc. Nurs.,2020